Transcode Therapeutics to Evaluate Strategic Alternatives
Transcode Therapeutics said it will evaluate licensing arrangements, development partnerships and other strategic transactions.
Related stories
Rubean Plans New-Share Placement
Rubean plans a prospectus-free placement of new shares.
L impact | EQUITY | Oct 29, 2026, 04:53 PM UTC
Manitou BF Announces Q3 2026 Revenue Release Availability
M impact | EQUITY | Oct 29, 2026, 04:53 PM UTC
Preformed Line Products Reports Third-Quarter Revenue of $209.5 Million
Preformed Line Products reported third-quarter 2026 revenue of $209.5 million, up 17.6% from $178.1 million a year earlier. Net income attributable to PLP shareholders rose to $18
M impact | EQUITY | Oct 29, 2026, 04:53 PM UTC
Eutelsat Misses Q3 Revenue Consensus, Confirms Outlook
Eutelsat missed Q3 revenue consensus and confirmed its outlook.
M impact | EQUITY | Oct 29, 2026, 04:52 PM UTC
Axis Trusteeship Gives Yes Bank Three Days to Restore AT-1 Bonds
Axis Trusteeship Services issued a notice on October 28 calling on Yes Bank’s MD and CEO and board to restore or reactivate AT-1 bonds written down in March 2020, aggregating Rs 8,
M impact | EQUITY | Oct 29, 2026, 04:52 PM UTC
Marie Brizard Q3 Revenue Rises 0.3%, Nine-Month Revenue Falls 2.9%
Unaudited Q3 2026 revenue rose 0.3% year over year, or 1.8% on a reported basis. Nine-month revenue was €125.6 million, down 2.9% year over year. France rose 13.3% in Q3 while Inte
M impact | EQUITY | Oct 29, 2026, 04:52 PM UTC